Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Novo Nordisk's blockbuster weight-loss drug shows promising results in a new age group. In a late-stage trial, more than 40% of children aged 6 to under 12 treated with semaglutide were no longer classified as obese after 68 weeks. The findings could open the door to expanded use of Wegovy in younger pediatric patients.
Novo Nordisk's semaglutide — the active ingredient in Wegovy — is making waves beyond its established adult and adolescent user base. Results from a late-stage clinical trial show that the drug significantly reduced obesity rates in children as young as 6, a population that has had very limited pharmacological treatment options until now.
The trial tracked children aged 6 to under 12 over 68 weeks, and the results were striking: assuming full adherence to treatment, 40.4% of participants were no longer classified as having obesity by the end of the study period. This builds on earlier data supporting semaglutide's efficacy in teens and adults, and could set the stage for a regulatory push to expand Wegovy's approved age range.
By the Numbers:
Why it matters: Childhood obesity is a major public health challenge with long-term consequences for cardiovascular health, metabolic disease, and mental well-being. Expanding effective pharmacological options to younger children could be a game-changer for pediatric care — though questions around long-term safety, access, and prescribing norms will need to be addressed.